Abbott Laboratories

NYSE:ABT

Medical - Devices

Healthcare
$104.48 -0.58%

-$0.51 today

Market cap
$180.95B
Beta
0.62
P/E (TTM)
24.5
EPS (TTM)
$3.59
Dividend yield
2.77%
52W Low $81.97High $139.06

Volume 7.02M

Average 13.17M

ABT Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Abbott LaboratoriesNYSE: ABT

Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026

Cost of revenue growth accelerates

Q3 FY2026 cost of revenue of $5.59B rose 11.1% year over year, ahead of the +2.5% change in trailing-twelve-month cost of revenue. Sequentially, it rose 5.7% from the prior quarter. Over 3 fiscal years it compounded at -2.6% a year.

Context

  • Cost of revenue amounted to 44.5% of revenue in FY2025, down 4.7 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +11.1% holds above the trailing-twelve-month pace of +2.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$5.59B+5.7% QoQ
Last fiscal yearDec 2025
$19.72B-4.4% YoY
LTMSep 2026
$20.68B+2.5% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.1%——
1 year-4.4%——
3-year CAGR-2.6%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
19.72B USD
Year-over-year change
-4.4%
4-year CAGR
-0.2%

Cost of Revenue vs competitors

How ABT compares with its peers on the latest reported figures

  • ABT's LTM Sep 2026 cost of revenue of $20.68B is the 3rd highest of the 10 companies compared; the peer median is $10.72B.
  • Its year-over-year change of +2.5% is the 5th highest of 10, against a peer median of +1.8%.
  • Cost of revenue amounts to 42.9% of revenue for ABT, versus a peer median of 34.8%.
ABT Competitors Peer median
Cost of Revenue for ABT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$30.98B +5.3%+7.1%31.2%
TMOThermo Fisher Scientific Inc.LTM Sep 2026$27.73B +6.5%+0.5%58.6%
ABTAbbott LaboratoriesLTM Sep 2026$20.68B +2.5%-2.6%42.9%
MDTMedtronic plcLTM Jul 2026$12.51B +0.0%+5.9%33.3%
GEHCGE HealthCare Technologies Inc.LTM Jun 2026$11.56B -1.0%+3.5%57.1%
BDXBecton, Dickinson and CompanyLTM Sep 2026$10.72B -10.1%-2.9%53.0%
DHRDanaher CorporationLTM Sep 2026$10.6B +12.9%-2.8%41.4%
SYKStryker CorporationLTM Jun 2026$9B +1.8%+6.9%34.8%
BSXBoston Scientific CorporationLTM Jun 2026$6.06B -11.0%+7.8%28.8%
EWEdwards Lifesciences CorporationLTM Jun 2026$1.44B +19.7%+4.4%22.0%
Peer median (excluding ABT) $10.72B+1.8%+4.4%34.8%

Competitors are the stored peer set for ABT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue43.08B43.65B40.11B41.95B44.33B
Cost of Revenue19.86B21.33B20.07B20.63B19.72B
Gross Profit23.21B22.32B20.04B21.33B24.61B
Gross Margin53.9%51.1%50.0%50.8%55.5%
Research & Development2.74B2.85B2.72B2.82B2.96B
Selling, General & Admin11.28B11.11B10.88B11.65B12.38B
Operating Expenses14.01B13.96B13.6B14.47B16.59B
Depreciation & Amortization3.54B3.27B3.24B3.22B3.12B
EBITDA12.16B11.89B10.61B10.83B11.92B
EBITDA Margin28.2%27.2%26.4%25.8%26.9%
Operating Income9.2B8.36B6.44B6.83B8.05B
Operating Margin21.4%19.2%16.0%16.3%18.2%
Interest Income43M183M385M344M230M
Interest Expense410M315M698M603M341M
Other Income / Expenses(989M)(56M)229M188M418M
Income Before Tax8.21B8.31B6.66B7.01B8.47B
Pre-Tax Margin19.1%19.0%16.6%16.7%19.1%
Income Tax Expense1.14B1.37B941M(6.39B)1.94B
Net Income7.07B6.93B5.72B13.4B6.52B
Net Margin16.4%15.9%14.3%31.9%14.7%
EPS (Basic)3.973.943.307.673.74
EPS (Diluted)3.943.913.277.643.72
Weighted Avg Shares1.78B1.75B1.73B1.73B1.75B
Weighted Avg Shares (Diluted)1.79B1.76B1.75B1.75B1.75B

Abbott Laboratories

NYSE:ABT

Intrinsic Alpha fair value

Locked

Current Price

$104.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.